Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial

Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial

Abstract Introduction We assessed effects of AZD7442 (tixagevimab/cilgavimab) on deaths from any cause or hospitalizations due to coronavirus disease 2019 (COVID-19) and symptom severity and longer-term safety in the TACKLE adult outpatient treatment study. Methods Participants received 600 mg AZD74...

Full description

Bibliographic Details
Main Authors: F. D. Richard Hobbs, Hugh Montgomery, Francisco Padilla, Jesus Abraham Simón-Campos, Kenneth Kim, Douglas Arbetter, Kelly W. Padilla, Venkatesh Pilla Reddy, Seth Seegobin, Katie Streicher, Alison Templeton, Rolando M. Viani, Eva Johnsson, Gavin C. K. W. Koh, Mark T. Esser
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-09-01
Series:Infectious Diseases and Therapy
Subjects:
COVID-19
Hospitalization
Monoclonal antibodies
SARS-CoV-2
Symptoms
AZD7442
Online Access:https://doi.org/10.1007/s40121-023-00861-7

Internet

https://doi.org/10.1007/s40121-023-00861-7

Similar Items